Q32 Bio Inc.

QTTB Nasdaq SEC CIK 1661998
Follow Q32 Bio Weekly email: filings, results

Financials

Reported figures only · latest: Q3 2026 USD · US GAAP
Net income −$8.9M −20.7% vs same quarter last year
EPS, diluted −$0.26 +56.7% vs same quarter last year
Operating cash flow −$4.4M −4.4% vs same quarter last year
Operating income −$10.7M −40.7% vs same quarter last year
Net income by quarter
−$14.2M
−$11M
−$9.5M
−$7.4M
$57.7M
−$7.6M
−$8.9M
−$8.9M
Q4 24 Q1 25 Q2 25 Q3 25 Q4 25 Q1 26 Q2 26 Q3 26

Source: SEC XBRL filings · latest filing

The long view

Fiscal years as reported · SEC XBRL filings, US GAAP
Revenue and net income10 fiscal years
  • Revenue
  • Net income
−$150M−$100M−$50M$0$50M$100MFY17FY19FY21FY23FY25
Show the numbers
YearRevenueNet income
FY25$53.7M$29.8M
FY24$0−$47.7M
FY23$1.2M−$53.7M
FY22$3.2M−$5M
FY21$34M−$95.8M
FY20$2.7M−$128.7M
FY19$1.7M−$103.9M
FY18$5.3M−$55.6M
FY17-−$30M
FY16--
MarginsShare of revenue
  • Operating margin
  • Net margin
−8000%−6000%−4000%−2000%0%2000%FY17FY19FY21FY23FY25
Show the numbers
YearOperating marginNet margin
FY2531.5%55.5%
FY24--
FY23−4174.3%−4645.3%
FY22−4154.6%−156%
FY21−282.4%−281.9%
FY20−4821%−4762.9%
FY19−6599.2%−6237.5%
FY18−1126%−1044.3%
FY17--
FY16--
Free cash flowOperating cash flow minus capital expenditure
−$150M−$100M−$50M$0$50MFY17FY19FY21FY23FY25
Show the numbers
YearFree cash flow
FY25−$33.5M
FY24−$67.8M
FY23−$18.7M
FY22−$114.9M
FY21−$112.1M
FY20−$98.1M
FY19−$113.2M
FY18−$67.5M
FY17$4.5M
FY16-
Net margin vs the sectorMedian of Healthcare companies filing with the SEC
  • Q32 Bio
  • Healthcare median
−8000%−6000%−4000%−2000%0%2000%FY17FY19FY21FY23FY25
Show the numbers
YearQ32 BioHealthcare median
FY2555.5%−30.6%
FY24-−47%
FY23−4645.3%−58%
FY22−156%−80.4%
FY21−281.9%−71.8%
FY20−4762.9%−62.2%
FY19−6237.5%−46.2%
FY18−1044.3%−49.6%
FY17-−45.9%
FY16-−36%